Abstract
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Original language | English (US) |
---|---|
Pages (from-to) | 610-614 |
Number of pages | 5 |
Journal | Protein and Peptide Letters |
Volume | 14 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2007 |
Keywords
- B-cell lymphoma
- CD20
- Immunotherapy
- Keyhole limpet hemocyanin (KLH)
- Mimotope
- Vaccine
ASJC Scopus subject areas
- Structural Biology
- Biochemistry